Evidence map›Paper›PMID 36992206›Full record

ReviewVaccines2023

Equity-Informative Economic Evaluations of Vaccines: A Systematic Literature Review.

Chanthawat Patikorn, Jeong-Yeon Cho, Philipp Lambach, Raymond Hutubessy, Nathorn Chaiyakunapruk

Open access · goldAbstract readReview
In one paragraph

Review in Vaccines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 4 countries.

Chanthawat PatikornDepartment of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT 84112, USA.ORCID 0000-0003-3502-4718
Jeong-Yeon ChoDepartment of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT 84112, USA.ORCID 0000-0003-1351-5006
Philipp LambachDepartment of Immunization, Vaccines and Biologicals (IVB), World Health Organization, 1211 Geneva, Switzerland.
Raymond HutubessyDepartment of Immunization, Vaccines and Biologicals (IVB), World Health Organization, 1211 Geneva, Switzerland.ORCID 0000-0002-9286-5065
Nathorn ChaiyakunaprukDepartment of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT 84112, USA.ORCID 0000-0003-4572-8794
University of Utah · USWorld Health Organization · CHChulalongkorn University · TH

Funding

World Health Organization 001
6 · The paper itself

Abstract

The Immunization Agenda 2030 prioritizes the populations without access to vaccines. Health equity has been increasingly incorporated into economic evaluations of vaccines to foster equitable access. Robust and standardized methods are needed to evaluate the health equity impact of vaccination programs to ensure monitoring and effective addressing of inequities. However, methods currently in place vary and potentially affect the application of findings to inform policy decision-making. We performed a systematic review by searching PubMed, Embase, Econlit, and the CEA Registry up to 15 December 2022 to identify equity-informative economic evaluations of vaccines. Twenty-one studies were included that performed health equity impact analysis to estimate the distributional impact of vaccines, such as deaths averted and financial risk protection, across equity-relevant subgroups. These studies showed that the introduction of vaccines or improved vaccination coverage resulted in fewer deaths and higher financial risk benefits in subpopulations with higher disease burdens and lower vaccination coverage-particularly poorer income groups and those living in rural areas. In conclusion, methods to incorporate equity have been evolving progressively. Vaccination programs can enhance equity if their design and implementation address existing inequities in order to provide equitable vaccination coverage and achieve health equity.

Indexed as

cost-effectiveness analysisdisparityeconomic evaluationequityimmunizationinequalityvaccine

Identifiers

PMID36992206
PMCPMC10057152
OpenAlexW4323843525

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.